Click [...] To view or add a comment, sign in $NVO has started a Phase 1 trial for its new obesity drug candidate LX9851, developed with Lexicon Pharmaceuticals The drug is oral and works differently from current GLP-1 treatments, targeting fat metabolism and satiety signals The study will assess safety in overweight and obese patients, with results expected in Q1 2027 Lexicon receives a $10M milestone payment and could earn up to $1B plus royalties if successful #stocks #Investing To view or add a comment, sign in 16,833 followers
However, NICE guidance does not recommend glutathione supplementation for NAFLD management, and it is not part of standard NHS treatment protocols
Incompatibility: Reactivity with other active ingredients or preservatives in complex cosmetic matrices
For example, HydroGlow Anti-Aging Night Mask is a leave-on night mask built around hydration-focused ingredients including three types of hyaluronic acid, polyglutamic acid, jojoba, squalane, aloe, sea silt ferment, and algae extract